NCT01457027View on ClinicalTrials.gov

A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Influenza
Interventions
BIOLOGICAL

Inflexal V

"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"

Trial Locations (1)

16100

"Dept. of Health Sciences, University of Genoa and Hygiene Unit, San Martino University Hospital", Genoa

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT01457027 - A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season | Biotech Hunter | Biotech Hunter